Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Stock analysts at William Blair cut their FY2025 earnings per share estimates for Bristol Myers Squibb in a report released on Monday, July 14th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings of $6.22 per share for the year, down from their prior estimate of $6.77. William Blair currently has a "Market Perform" rating on the stock. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.74 per share. William Blair also issued estimates for Bristol Myers Squibb's FY2026 earnings at $6.28 EPS.
Several other research firms have also recently commented on BMY. Morgan Stanley reduced their price target on Bristol Myers Squibb from $36.00 to $34.00 and set an "underweight" rating for the company in a report on Thursday, July 10th. Jefferies Financial Group reduced their price target on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. The Goldman Sachs Group reissued a "neutral" rating and issued a $55.00 price target (down from $67.00) on shares of Bristol Myers Squibb in a report on Tuesday, April 8th. Piper Sandler assumed coverage on Bristol Myers Squibb in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price target for the company. Finally, Cantor Fitzgerald reissued a "neutral" rating and issued a $55.00 price target on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $57.69.
Check Out Our Latest Stock Analysis on Bristol Myers Squibb
Bristol Myers Squibb Stock Performance
Bristol Myers Squibb stock traded up $0.73 during mid-day trading on Tuesday, reaching $47.16. 6,176,064 shares of the company were exchanged, compared to its average volume of 12,784,780. Bristol Myers Squibb has a twelve month low of $40.09 and a twelve month high of $63.33. The firm's 50-day simple moving average is $47.43 and its two-hundred day simple moving average is $53.10. The company has a debt-to-equity ratio of 2.65, a quick ratio of 1.17 and a current ratio of 1.28. The firm has a market cap of $95.97 billion, a PE ratio of 17.66, a price-to-earnings-growth ratio of 2.42 and a beta of 0.36.
Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The business's quarterly revenue was down 5.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($4.40) EPS.
Bristol Myers Squibb Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.26%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's payout ratio is 92.88%.
Insiders Place Their Bets
In related news, EVP Samit Hirawat purchased 4,250 shares of the company's stock in a transaction on Friday, April 25th. The stock was bought at an average price of $47.58 per share, with a total value of $202,215.00. Following the completion of the transaction, the executive vice president owned 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This represents a 5.36% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.07% of the company's stock.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Polar Asset Management Partners Inc. acquired a new position in shares of Bristol Myers Squibb during the fourth quarter worth about $16,651,000. Avaii Wealth Management LLC lifted its stake in shares of Bristol Myers Squibb by 590.9% during the first quarter. Avaii Wealth Management LLC now owns 78,597 shares of the biopharmaceutical company's stock worth $4,794,000 after purchasing an additional 67,221 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Bristol Myers Squibb by 1.4% during the first quarter. Assenagon Asset Management S.A. now owns 65,038 shares of the biopharmaceutical company's stock worth $3,967,000 after purchasing an additional 869 shares in the last quarter. Shorepoint Capital Partners LLC lifted its stake in shares of Bristol Myers Squibb by 2.2% during the fourth quarter. Shorepoint Capital Partners LLC now owns 58,426 shares of the biopharmaceutical company's stock worth $3,305,000 after purchasing an additional 1,248 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in shares of Bristol Myers Squibb by 17.0% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 550,613 shares of the biopharmaceutical company's stock worth $33,582,000 after acquiring an additional 80,087 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.
About Bristol Myers Squibb
(
Get Free Report)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Further Reading
Before you consider Bristol Myers Squibb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.
While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
